Brainstorm Cell Therapeutics Reports Q1 2025 Financials

Brainstorm Cell Therapeutics ( (BCLI) ) has released its Q1 earnings. Here is a breakdown of the information Brainstorm Cell Therapeutics presented to its investors.

Brainstorm Cell Therapeutics Inc. is a biotechnology company focused on developing autologous cellular therapies for neurodegenerative diseases, including ALS, PMS, and Alzheimer’s disease, using its proprietary NurOwn® technology. In its latest earnings report, Brainstorm Cell Therapeutics highlighted a significant increase in cash and cash equivalents, reaching $1.644 million as of March 31, 2025, compared to $187,000 at the end of 2024. The company reported a net loss of $2.864 million for the first quarter of 2025, an improvement from the $3.401 million loss in the same period last year. Brainstorm’s financial strategy involved raising funds through at-the-market offerings and warrant exercises, contributing to a total of $3.086 million in financing activities. Despite the ongoing challenges, Brainstorm is actively pursuing regulatory approval for its NurOwn® treatment for ALS and is preparing for a potential Phase 3b trial. Looking ahead, the company remains focused on securing additional capital and advancing its clinical programs to achieve long-term growth and sustainability.